Promising new attack on tough breast cancer brain metastases

NCT ID NCT06238921

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding two drugs (sacituzumab govitecan and zimberelimab) to precise brain radiation can help people with metastatic triple negative breast cancer that has spread to the brain. The trial will enroll 31 adults and compare the combination against sacituzumab govitecan alone. Researchers will monitor safety and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sacituzumab govitecan (Trodelvy) and zimberelimab
What this could lead to: If successful, this combination could offer a new treatment option that helps control both brain and body tumors in people with metastatic triple negative breast cancer.
What could go wrong: This is an early-phase trial with only 31 participants, so results may not apply to everyone. The added drugs and radiation may cause serious side effects like neurological toxicity or radionecrosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.